Yan-Qun Xiang Selected Research

Yan-Qun Xiang Research Topics

Disease

63	Nasopharyngeal Carcinoma 02/2024 - 10/2004
27	Neoplasms (Cancer) 02/2024 - 03/2004
26	Neoplasm Metastasis (Metastasis) 02/2024 - 03/2004
3	Mucositis 01/2022 - 01/2017
2	Necrosis 08/2023 - 01/2016
2	Vomiting 01/2022 - 01/2018
2	Disease Progression 01/2022 - 01/2020
2	Nausea 01/2022 - 01/2018
2	Carcinogenesis 01/2019 - 01/2017
1	Hypertension (High Blood Pressure) 08/2023
1	Anaphylaxis (Anaphylactic Shock) 08/2023
1	Hemorrhage 08/2023
1	Pruritus (Itching) 08/2023
1	Fatigue 01/2022
1	Anemia 01/2022
1	Hand-Foot Syndrome 01/2022
1	Liver Neoplasms (Liver Cancer) 01/2021
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Neutropenia 01/2021
1	Anorexia 01/2018
1	Ototoxicity 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Weight Loss (Weight Reduction) 01/2017
1	Candidiasis (Moniliasis) 01/2017
1	Sinusitis 08/2008
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2004

Drug/Important Bio-Agent (IBA)

11	DNA (Deoxyribonucleic Acid)IBA 10/2022 - 04/2013
10	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2014
6	PlatinumIBA 08/2023 - 02/2010
6	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 02/2010
6	Indicators and Reagents (Reagents)IBA 01/2020 - 10/2004
5	3-nitrophenyl 3-piperidinecarboxylate (MNPC)IBA 08/2023 - 01/2013
4	Capecitabine (Xeloda)FDA Link 10/2022 - 01/2022
3	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2021
3	C-Reactive ProteinIBA 10/2023 - 01/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2023 - 10/2004
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2011
3	Carboplatin (JM8)FDA LinkGeneric 01/2016 - 02/2010
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2023 - 01/2021
2	AntibodiesIBA 08/2023 - 11/2015
2	IntegrinsIBA 01/2023 - 01/2019
2	Neurofibromin 2 (Merlin)IBA 01/2023 - 01/2019
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2022 - 08/2013
2	lobaplatinIBA 01/2021 - 01/2017
2	Docetaxel (Taxotere)FDA Link 01/2016 - 02/2010
1	apatinibIBA 02/2024
1	Angiogenesis InhibitorsIBA 02/2024
1	camrelizumabIBA 02/2024
1	sintilimabIBA 08/2023
1	Bevacizumab (Avastin)FDA Link 08/2023
1	BilirubinIBA 08/2023
1	Complement System Proteins (Complement)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Polo-Like Kinase 1IBA 01/2019
1	BI 6727IBA 01/2019
1	taxaneIBA 10/2018
1	nedaplatinIBA 01/2018
1	130-nm albumin-bound paclitaxelIBA 01/2017
1	potassium hydroxideIBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	SolventsIBA 01/2017
1	Cetuximab (Erbitux)FDA Link 01/2017
1	Albumin-Bound Paclitaxel FDA Link 01/2017
1	Hepatitis B Core AntigensIBA 11/2015
1	Urokinase Plasminogen Activator ReceptorsIBA 01/2014
1	Matrix Metalloproteinases (MMPs)IBA 12/2013
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 12/2013
1	Proteins (Proteins, Gene)FDA Link 04/2013
1	raf KinasesIBA 04/2013
1	Small Interfering RNA (siRNA)IBA 07/2012
1	Interleukin-8 (Interleukin 8)IBA 07/2012
1	Proteoglycans (Proteoglycan)IBA 04/2011
1	serglycinIBA 04/2011
1	ProteomeIBA 08/2010
1	Immunoglobulin A (IgA)IBA 02/2006
1	ErbB Receptors (EGF Receptor)IBA 11/2004
1	Tyrosine Kinase InhibitorsIBA 11/2004
1	Gefitinib (Iressa)FDA Link 11/2004
1	anilinoquinazolineIBA 11/2004

Therapy/Procedure

21	Chemoradiotherapy 02/2024 - 10/2009
19	Radiotherapy 10/2023 - 03/2004
16	Drug Therapy (Chemotherapy) 10/2023 - 02/2010
13	Induction Chemotherapy 02/2024 - 10/2009
7	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021 - 12/2015
5	Therapeutics 10/2023 - 12/2011
2	TP protocol 01/2022 - 01/2022
2	Precision Medicine 01/2017 - 04/2011
2	Aftercare (After-Treatment) 06/2011 - 11/2004
1	Immunotherapy 02/2024
1	Combination Drug Therapy (Combination Chemotherapy) 01/2023
1	Adjuvant Chemotherapy 10/2022
1	Neoadjuvant Therapy 01/2017
1	Re-Irradiation 01/2016
1	Lasers (Laser) 08/2010